54 results about "Immune Factors" patented technology

The invention belongs to the technical field of bioengineering, and particularly relates to leuconostoc mesenteroides subsp. Mesenteroides FTCM002 and application thereof in preparation of dendrobium officinale leavening with the effects of reducing blood sugar, nourishing the stomach and resisting inflammation. Dendrobium officinale is subjected to enzymolysis and inoculated with the strain for fermentation, and the obtained fermented dendrobium officinale has the effect of inhibiting alpha-glucosidase; the gastric mucosal injury can be relieved, the expression of VEGF, IL-6, IL-8 and TNF-alpha in the gastric mucosal injury is reduced, and the effect of nourishing the stomach is achieved; the cell phagocytic rate can be increased, the NO concentration and the content of immune factors IL-6 and TNF-alpha can be increased, and the effect of enhancing the immunity is achieved; the expression quantity of IL-6, IL-1beta and TNF-alpha in inflammatory cells can be reduced, and the anti-inflammatory effect is achieved.

The invention discloses a giant salamander immune regulation meat peptide and application thereof. The meat peptide comprises one or more than two polypeptides selected from SEQ ID NOs: 1-5. The polypeptide can enhance cellular immune response, such as enhancing macrophage proliferation activity, improving macrophage nitric oxide secretion level, enhancing macrophage phagocytic ability, enhancing macrophage antigen presentation ability, enhancing immune organ functions, regulating T cell subpopulation, improving cellular immune factor level and enhancing immune globulin level.

The invention belongs to the technical field of radiooncology, artificial intelligence and medical image fusion, and particularly relates to a model construction method and system for predicting the radiation pneumonitis risk of a patient receiving immune combined radiotherapy. According to the method, for a non-small cell lung cancer patient receiving immune checkpoint inhibitor (ICIs) combined radiotherapy, clinical information and radiotherapy dose parameters of the patient are collected, a positioning CT image and dynamic immune factor data are simulated, multi-source features including radiomics features, an immune change curve and dose volume indexes are extracted, and a multi-modal fusion prediction model is constructed. The system integrates automatic data input, feature extraction, model training and risk output modules, can output individual radiation pneumonitis risk scores, provides risk grading and dose intervention suggestions, and has high prediction accuracy and clinical interpretability. The method can be widely applied to individualized risk management and precise treatment of non-small cell lung cancer immune combined radiotherapy patients.

The invention discloses a biological preparation suitable for young pigeon growth and a preparation method and application thereof, and belongs to the technical field of feeds, the biological preparation comprises the following components by weight: 8-40 parts of a microbial agent, 1-10 parts of an additive, 1-10 parts of an antioxidant, 0.5-5 parts of peptidoglycan, and 40-60 parts of montmorillonite; the microbial agent comprises bifidobacterium animalis, lactobacillus acidophilus, lactobacillus paracasei and lactobacillus reuteri; the additive comprises at least one of yeast beta-glucan and astragalus polysaccharide. According to the biological preparation suitable for young pigeon growth, montmorillonite is used as a base material, under the combined action of the microbial inoculum, the additive, the antioxidant and peptidoglycan, the biological preparation capable of adjusting intestinal health of breeding pigeons and improving the immunity of the breeding pigeons is obtained, meanwhile, immune factors in pigeon milk can be improved, and the growth of young pigeons is promoted. The effects of improving the growth performance of the young pigeons and reducing the elimination rate of the breeding pigeons and the young pigeons can be achieved, so that economic benefits are improved, and wide application prospects are achieved.

The application provides a construction method of a humanized keloid mouse model, comprising the following steps: BAC plasmid construction and preparation; superovulation of experimental mice and collection of zygotes; pronuclear microinjection of zygotes; post-injection embryo transplantation; genotype identification; breeding and genetic analysis; and verification of construction results of the humanized immune system by immunohistochemistry and immunofluorescence. In the application, peripheral blood mononuclear cells treated by sCD27 and skin around keloids (homologous cells and tissues) are transplanted into NSG-MHC-DKO immune-deficient mice with overexpression of CD70 genes, so that HLA rejection of different homologous immune cells and tissues can be avoided, the internal microenvironment of keloids and the interaction between the internal microenvironment and the immune system can be restored to the maximum extent, and the influence of immune factors on the occurrence and development of keloids can be realized in vitro. The application first discovers and verifies that the activation of the CD27-CD70 axis can promote the occurrence and development of keloids, and provides a suitable animal model for the research and development of anti-keloid drugs, especially immunotherapy.

The invention provides application of M1 protein related substances in preparation of medicines for treating diseases caused by avian influenza viruses. The application is any one of the following applications: application of Y1 in preparation of medicines for preventing and / or treating diseases caused by avian influenza viruses or avian influenza virus infection; the Y2 is applied to preparation of an avian influenza virus inhibitor; the invention discloses application of Y3 in inhibition of avian influenza virus replication. After a mouse is immunized by the M1 recombinant protein, immune factors related to T cells are increased, secretion of proinflammatory factors is reduced, preparation is made for protecting a body from virus attack, and the M1 recombinant protein is also an expression for laterally improving the immunity of a host. The M1 protein has a good immune effect as an immunogen. The invention has application value in treatment of avian influenza virus and similar viruses.

The present application relates to the field of microbial technology, and particularly relates to bifidobacterium BB36 with improved antigen presentation ability and enriched calcium, iron and selenium, probiotics and application thereof. Bifidobacterium bifidum The present application provides bifidobacterium BB36 with activated macrophages, up-regulated immune factor expression level, and activated dendritic cells, enhanced antigen presentation ability in immune process, and enriched calcium, iron and selenium, and can be used as a biological carrier of mineral elements, in addition, can inhibit the growth of escherichia coli and staphylococcus aureus, and protect intestinal health of the body.

The invention provides an application and a method of an RSAD2 agonist glycopyrronium in resisting RSV infection. The method comprises the following steps: S1, virtual screening and molecular docking; s1.1, performing virtual screening and molecular docking; s1.2, carrying out molecular dynamics simulation; s2, cell culture and RSV infection; s3, performing RT-qPCR detection on the expression of the RSAD2 and the virus load of the RSV; s4, performing Westernblot analysis on the influence of a small molecule compound on the expression of the RSAD2; s5, CCK8 is used for detecting the toxicity of the compound to Beaas-2b cells; s6, carrying out indirect immunofluorescence detection on a fluorescence signal of the RSV; s7, animal model establishment; s8, carrying out HE dyeing; s9, carrying out enzyme-linked immunosorbent assay (ELISA); and S10, statistical analysis. According to the present invention, the small molecule agonist targeting the host immune factor RSAD2 is screened, the endogenous antiviral factor is activated from the host perspective, the drug resistance problem caused by direct virus targeting is avoided, the RSAD2 is adopted as the host natural antiviral molecule, the activation strategy has good targeting property and good safety, and the efficient anti-RSV effect under the low toxic-side effect is achieved.

The invention discloses immune factor detection test paper and a preparation method thereof, and relates to the technical field of biomedicine. The test paper structurally comprises a bottom plate, a sample pad, a binding pad, a nitrocellulose membrane and absorbent paper, and multi-index joint detection is realized by coating a specific detection antibody on the binding pad and coating a specific capture substance on a detection line. The test paper has the advantages of simplicity and convenience in operation, rapidness in detection, multi-index joint detection and the like, and can provide powerful support for diagnosis of immune-related adverse reactions and other diseases.

This application belongs to the field of microbial technology, and mainly relates to a strain of *Pediococcus lactis* BPA03 and its applications. *Pediococcus lactis* BPA03 is classified and named *Pediococcus lactis*. Pediococcus acidilactici This *Pediococcus lactis* strain BPA03 was deposited on September 28, 2025, at the China General Microbiological Culture Collection Center (CGMCC), located at No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing, with accession number CGMCC No. 36109. It inhibits skin melanin deposition and improves UV photoaging, suppresses the gene expression levels of immune factors such as IL-1β, IL-6, IL-8, and TNF-α, improves the activities of superoxide dismutase, catalase, and glutathione peroxidase, inhibits vinorelbine-induced neutropenia, and improves the inhibition of immune factor expression induced by vinorelbine, thus exhibiting comprehensive anti-aging effects.

The invention discloses a duck plague virus LORF2 gene deleted strain as well as a construction method and application thereof, and belongs to the technical field of gene engineering. The construction method comprises the following steps: S1, by taking a pEP-Kan-S plasmid as a template, carrying out PCR (Polymerase Chain Reaction) amplification on a delta LORF2-Kan targeting fragment; s2, electrically transferring the targeting fragment to a competent state to construct a positive bacterium of which the LORF2 gene is replaced by a Kan resistance gene; s3, knockout of Kan resistance genes through homologous recombination; and S4, carrying out virus rescue to obtain the LORF2 gene deleted strain. The duck plague virus LORF2 gene deletion strain constructed by the invention has reduced pathogenicity to ducks and high immune factor level, can completely protect the ducks from being attacked by virulent viruses by immunizing the ducks with an ultra-low dose of 102 TCID50, has a virulent virus removal effect and a neutralizing antibody level which are similar to those of an existing commercial vaccine group, and provides strains, thoughts and technical supports for construction of DPV attenuated live vaccines.

The application discloses a quinazoline-4(3H)-ketone compound and a preparation method, a pharmaceutical composition and application thereof, the structure of the compound is as shown in the formula (I), and the compound comprises isomers, pharmaceutically acceptable salts or mixtures thereof. The compound and the pharmaceutical composition thereof have a high inhibitory effect on PARP7, the inhibitory activity reaches a nanomolar concentration level, can significantly promote the release of immune factors, are used for immunotherapy of tumors, and can exert good drug efficacy at a molecular level and a cell level. In addition, the preparation method of the compound is simple and easy to implement.

This invention belongs to the field of active ingredient extraction and purification technology, specifically a neutral polysaccharide ORP-0 from *Agaricus bisporus* and its applications. The preparation method of this invention includes the following steps: (1) pretreatment; (2) polysaccharide extraction; (3) impurity removal; and (4) separation and purification. This invention obtains a single neutral polysaccharide ORP-0 through defatting pretreatment, ultrasonic-assisted extraction, multiple impurity removal processes, and separation and purification using a DEAE-52 cellulose chromatography column. The method of this invention is simple to operate, has mild reaction conditions, and a complete impurity removal process. The obtained neutral polysaccharide has high purity, with a total sugar content of 92.09%. Furthermore, the obtained neutral polysaccharide ORP-0 enhances the activity of RAW 264.7 macrophages, increases the release of immune factors, enhances the expression of phosphorylated proteins in the MAPK signaling pathway, and activates the body's immune response.

The invention discloses an application of a combination of a ficus pandurata aqueous extract and a PD-1 antibody in preparation of a medicine for preventing or treating colorectal cancer. The ficus pandurata water extract and the PD-1 antibody are creatively combined for use, and experimental results show that on one hand, the combination of the ficus pandurata water extract and the PD-1 antibody can synergistically inhibit tumor growth, improve the anti-tumor immune cell factor level and remarkably enhance the treatment effect on the colorectal cancer CRC; a new direction is provided for breaking through the clinical bottlenecks that the colorectal cancer CRC immunotherapy is low in response rate and limited in single-drug curative effect; on the other hand, the combination of the two drugs has no obvious toxic and side effects on heart, lung, liver and kidney, can reduce adverse effects on the spleen, has a potential protection effect on the important immune organ of the spleen, and is helpful to maintain the normal immune function of the organism.

The invention belongs to the technical field of detection, and particularly discloses a measurement uncertainty evaluation method for measuring immune factors in serum by an ELISA (enzyme-linked immuno sorbent assay) method. According to the method, ELISA detection is carried out on immune factors (such as IL-1beta) in serum of an experimental animal in contact with a medical instrument according to standards such as GB / T16886.20-2015, system analysis comprises nine types of uncertainty sources such as repeated detection, standard substance preparation and sample dilution, the standard uncertainty of each component is calculated through mathematical methods such as rectangular distribution and a least square method, and the standard uncertainty of each component is calculated according to the standard uncertainty. And synthesizing the standard uncertainty and calculating the expansion uncertainty, and finally outputting a standard detection result. The method comprehensively covers the uncertainty source, is rigorous in computational logic and clear in key quality control factors, provides a scientific and complete uncertainty evaluation scheme for medical instrument immunogenicity evaluation and immune factor determination in other experimental scenes, is beneficial to laboratory quality control and detection result optimization, and has wide practicability.

The invention relates to the technical field of deep learning, and discloses a prediction method and system for a liver cancer immunotherapy effect. The method comprises the following steps: carrying out multiple immunofluorescence staining pretreatment on a clinical sample, and collecting forward scattering data, lateral scattering data and multi-channel fluorescence data of mononuclear cells to obtain a cell expression initial data matrix; performing standardization processing to obtain a multi-dimensional feature matrix expressed by the immune factors; performing Bayesian network analysis, calculating a conditional probability relation and a mutual information value between immune cell factors, and constructing an immune factor association network; performing anomaly detection to obtain an immune factor expression anomaly detection result; and performing minimum tail boundary analysis on the immune factor expression anomaly detection result, solving an optimal risk boundary through a semi-definite programming model, and outputting immune factor anomaly quantitative evaluation data, thereby realizing quantitative risk evaluation of the prediction result and refined grading of the prediction result.

The invention discloses a functional food for improving immunity and belongs to the field of health-care foods. Comprising the following substances in parts by weight: 15-20 parts of chitosan oligosaccharide, 4-6 parts of astragalus polysaccharide, 2-4 parts of lucid ganoderma oligosaccharide, 2-4 parts of Chinese wolfberry oligosaccharide, 1-2 parts of codonopsis pilosula polysaccharide, 2-4 parts of ginseng oligosaccharide, 6-8 parts of lentinan, 6-10 parts of Chinese yam polysaccharide, 2-4 parts of oat peptide, 1-2 parts of pericarpium citri reticulatae polysaccharide, 6-8 parts of soybean peptide and 10-15 parts of whey protein peptide. The various components have a synergistic effect, the polysaccharide components can enhance the activity of immune cells, the peptide substances can promote the generation of immune factors, and the synergistic effect of the polysaccharide components and the peptide substances is beneficial for improving the immune defense capability of the body and improving the immunity of the human body.

The invention discloses application of oxidized berberine and neohesperidin in improving intestinal health of broiler chickens, and belongs to the technical field of feed additives. Research finds that oxidized berberine and neohesperidin can increase the intestinal villus height, crypt depth and goblet cell number of broiler chickens and improve intestinal health; the slaughter indexes such as daily weight gain and feed intake can be improved, the feed-weight ratio is reduced, and the slaughter indexes such as carcass weight and semi-eviscerating weight are increased; meanwhile, the serum immune factor and antioxidant index level is improved, the safety is high, and no obvious toxicity exists; and the two components are combined for use, so that a synergistic interaction effect is also achieved. The invention provides a new raw material resource for improving the intestinal health of the broiler chicken and improving the production performance and economic value of the broiler chicken.

The construction method comprises the following steps: amplifying a Cwp8 protein gene on a clostridium difficile genome, constructing the Cwp8 protein gene on a pLEB124 plasmid to obtain a recombinant plasmid pLEB124-Cwp8, and transferring the recombinant plasmid pLEB124-Cwp8 into lactococcus lactis F44 to obtain the clostridium difficile resistant lactococcus lactis, which is named as Lla-Cwp8, and the clostridium difficile resistant lactococcus lactis is named as Lla-Cwp8, and the clostridium difficile resistant lactococcus lactis is named as Lla-Cwp8. The surface of the Lla-Cwp8 disclosed by the invention can express the adhesion protein and realize high yield of Nisin. Experiments prove that Lla-Cwp8 has strong competition, rejection and translocation capabilities on clostridium difficile in vitro, can effectively reduce the survival rate of clostridium difficile and reduce colon shortening in vivo, can significantly reduce the expression of virulence proteins TcdA and TcdB and the expression of immune factors TNF-alpha and IL-6, and has a treatment effect on clostridium difficile infection.

The application belongs to the field of marine biotechnology, and particularly relates to natural polysaccharide-quaternized chitosan nanoparticles with immune stimulation and preparation and application thereof. The nanoparticles formed by natural polysaccharide with negative charge and quaternized chitosan with positive charge are obtained by polyelectrolyte complexation, the particle size is 316.4 nm, and the potential is 31.1 mV; the quaternized chitosan with positive charge and the natural polysaccharide with negative charge are mixed in a mass ratio of 6.25-10:1-4. After immunization of mice, the secretion amount of immunoglobulin IgG and immune factors in the mice is determined, which shows that the nanoparticles have good immune activity, thereby playing an effect in vaccine adjuvant. The application provides a method and guidance for the research on natural polysaccharide and chitosan derivatives as immune adjuvants in recent years.

The application discloses a Bifidobacterium breve capable of relieving psoriasis and an application thereof, and belongs to the technical field of microorganisms. The application screens a Bifidobacterium breve CCFM683, and the Bifidobacterium breve CCFM683 has the effect of relieving psoriasis caused by imiquimod, which is specifically embodied in the following aspects: (1) significantly reducing the weight loss of psoriasis mice; (2) significantly improving the pathological characteristics such as scales, thickening and redness of the skin of psoriasis-like mice; (3) regulating the level of skin immune factors of psoriasis-like mice; and (4) significantly inhibiting the proliferation of keratinocytes of the skin of psoriasis mice. The Bifidobacterium breve CCFM683 has great application prospect in the preparation of food or medicine for preventing and / or treating psoriasis.

Disclosed in the present invention are a pyridazinone compound and a preparation method therefor, a pharmaceutical composition thereof, and an application thereof. The pyridazinone compound has a structure as shown in formula (I), and contains an isomer thereof, a pharmaceutically acceptable salt thereof, or a mixture of the isomer and the pharmaceutically acceptable salt. The pyridazinone compound has excellent pharmacokinetic properties in vivo, can also promote the release of immune factors, and in particular, also has excellent antitumor activity in vivo. In addition, the preparation method for the pyridazinone compound is simple and easy.

The invention belongs to the technical field of microbial engineering, and particularly relates to leuconostoc mesenteroides subsp. Mesenteroides YWN-1 with the effects of benefiting qi, nourishing blood and enhancing immunity and application of the leuconostoc mesenteroides subsp. Mesenteroides YWN-1. The preservation number of the leuconostoc mesenteroides subsp. Mesenteroides YWN-1 is CGMCC No.34608. The leuconostoc mesenteroides subsp. Mesenteroides YWN-1 can significantly improve immune organ thymus and spleen injuries caused by deficiency of qi and blood, increase the number of red blood cells, hemoglobin and platelets of mice with deficiency of qi and blood, and have the efficacy of improving deficiency of both qi and blood. The phagocytic index, the serum hemolysin content, the half hemolysis value and the immune factor IgG and IgM content of mice with low immunity are improved, and the effects of improving immunity and resistance are achieved.

The invention relates to the technical field of livestock embryo engineering, in particular to an immune factor combination capable of improving bovine in-vitro embryo development efficiency and application, and the combination comprises IL-1alpha and IL-10. The culture medium is mainly composed of proinflammatory factor interleukin-1 alpha (IL-1 alpha) and anti-inflammatory factor interleukin-10 (IL-10) which are secreted by macrophages, and the deficiency of an immune regulation mechanism in a traditional in-vitro embryo culture system is effectively made up by simulating an immune microenvironment of in-vivo embryo development; the bovine in-vitro embryo culture process is obviously optimized, the excellent application potential is shown in the aspect of improving the embryo development efficiency and quality, and a brand new solution is provided for breaking through the bottleneck of the existing in-vitro embryo culture technology.

The invention provides a combined vaccine based on Th1 / Th2 immune dynamic equilibrium as well as a preparation method and application of the combined vaccine. Subcutaneous delivery of interleukin 12 (IL12) and antigen (such as ovalbumin OVA) mRNA is adopted in the early stage of tumor occurrence, so that specific antigen recognition and T cell immune response of an organism are activated; when immune response enters a function decline stage, the tumor microenvironment is regulated through intratumor delivery of interleukin 4 (IL4) mRNA, the metabolic activity of T cells is maintained, and the depletion of the T cells is delayed. Through space (subcutaneous / intra-tumor) and time (early stage / middle stage) separated delivery of different immune factors, 'start-steady state maintenance 'type immune stylization regulation and control are realized, antigen-specific CTL reaction and persistent anti-tumor effect are remarkably enhanced, and the problem of immune bias caused by independent use of the antigen-specific CTL reaction and the persistent anti-tumor effect is solved.

Provided is a high-yield method and kit for preparing mRNA by reducing or inhibiting double-stranded ribonucleic acid (dsRNA) formation during in vitro transcription. The preparation method is to add solid phase media during a transcription process. Compared with the existing technology, the present invention has the following advantages: according to the high-yield method and kit for preparing mRNA, different types of negatively charged solid phase media are added during the in vitro transcription, reducing the production of dsRNA by interface regulation, and improving the yield and stability of mRNA; in addition, the transfection efficiency of the mRNA prepared by solid phase regulation is improved, and the expression of immune factors is reduced. The solid phase media used in the method and kit are insoluble in water and do not contaminate the transcription system; after the transcription is completed, the solid phase media can be easily separated, and the operation is simple; after proper treatment, the solid phase media can be reused, thus the method and kit have low costs and can be easily scaled up to industrial-scale production.

The invention relates to the technical field of immune prevention and control, in particular to application of a single-stranded DNA adjuvant in preparation of a vaccine for protecting animals from being infected by pathogenic bacteria. In the invention, the single-stranded DNA adjuvant comprises more than one section of ssDNA motif; the ssDNA motif comprises a Hind III restriction enzyme cutting site sequence, a random ssDNA sequence and a polyG sequence; wherein the single-stranded DNA adjuvant has an annular structure, and is in a nano-particle state. The single-stranded DNA adjuvant is synthesized in a rolling circle amplification mode, efficient preparation of the single-stranded DNA adjuvant is achieved, and the synthesis cost of the single-stranded DNA adjuvant is reduced; the single-stranded DNA adjuvant provided by the invention has good stability and biological safety, can be swallowed by macrophages under a naked delivery condition, can effectively up-regulate the expression of immune factors, is composed of single-stranded DNA composed of a plurality of motifs with different numbers, has the potential of serving as a vaccine adjuvant, and can be used as a vaccine adjuvant. The immune protection effect of the Edwardsiella tarda inactivated vaccine can be obviously enhanced.

The invention relates to the technical field of microorganisms, and provides a lactobacillus acidophilus BB06 capable of enhancing immunity and conditioning intestinal tracts and application of the lactobacillus acidophilus BB06, and the preservation number of the lactobacillus acidophilus BB06 is CGMCC (China General Microbiological Culture Collection Center) No.34367. The lactobacillus acidophilus BB06 has the advantages that the lactobacillus acidophilus BB06 can be used for enhancing immunity and conditioning intestinal tracts; the lactobacillus acidophilus BB06 can remarkably improve the level of immune factors of zebra fish and improve the richness of lactobacillus and the like in the intestinal tract of the zebra fish, can grow by using various oligosaccharides as a unique carbon source and generate short-chain fatty acid, has good DPPH free radical scavenging capacity, hydrophobic acting force, cell membrane forming capacity and artificial gastric juice tolerance, and can be used for preparing the lactobacillus acidophilus BB06. The strain can provide a new probiotic source for development of products with functions of enhancing immunity, conditioning intestinal tracts and resisting oxidation, and has important application value.

The invention relates to the technical field of microorganisms, and provides a lactobacillus rhamnosus B12 with the effects of resisting allergy, enhancing immunity, conditioning intestinal flora and fermenting and application of the lactobacillus rhamnosus B12. The preservation number of the strain is CGMCC No.34366. The strain is wide in carbon source growth adaptability, has good short-chain fatty acid secretion level, biofilm forming ability, DPPH free radical scavenging ability and gastric juice and pancreatic juice tolerance, can promote expression of various immune factors of zebra fish, reduce the immune globulin IgE level, can optimize the intestinal flora structure, and can improve the immunity of the zebra fish. A good bacteriostatic effect is achieved on harmful pathogenic bacteria; in addition, various plant bases can be fermented, the SOD activity, the substrate chromaticity and the flavor quality of a fermented product are improved, and the content of red wolfberry protein and total amino acid is remarkably increased. The strain can provide a new probiotic source for the development of anti-allergic products, immunity enhancing products, intestinal flora conditioning products, antioxidant products, antibacterial products and fermented products.